Sorry, your browser is out of date. To view this page correctly, please install a modern browser (Microsoft Edge, Firefox or Google Chrome).
SAI - Detailed view
Please log in as a company employee using your SIMIS-Login. For further information please see the FAQ.
TECENTRIQ subkutan Inj Lös 1875 mg/15 ml Durchstf
Drug
TECENTRIQ subkutan, Injektionslösung
Onkologikum
07.16.1. – cytostatics
HAM – Human medicine
LSINJ – Solution for injection
BT – biological medicines
A – Dispensed once only on prescription by a physician or veterinarian (A)
Z – approved
8/5/2024
8/4/2029
Dosage strength
TECENTRIQ subkutan 1875 mg/15ml, Injektionslösung zur subkutanen Anwendung
Onkologikum
01
Z – approved
Package
7680692620019
In trade from / since 8/5/2024
A/R – Authorised / referenced
1 vial(s)
001
Z – approved
Declaration
Component
1875 mg atezolizumabum
hyaluronidasum humanum ADNr
histidinum
acidum aceticum 30 per centum
saccharum
polysorbatum 20
methioninum
aqua ad iniectabile
histidinum
acidum aceticum 30 per centum
saccharum
polysorbatum 20
methioninum
aqua ad iniectabile
Spezialitätenliste***
SL
-
-
4769.45
None
Yes
10%
No
Authorisation holder
7601001010208
Roche Pharma (Schweiz) AG
Grenzacherstrasse 124
4058 Basel (BS)
Grenzacherstrasse 124
4058 Basel (BS)
Date of revision of the text
5/9/2025
Please log in as a company employee using your SIMIS-Login. For further information please see the FAQ.
Data source: Swissmedic, *authorisation holder, **Refdata foundation, ***FOPH.